Surface-expressed allergen peptides or hypoallergenic allergen derivatives devoid of any IgE cross-linking might be ideal candidates in this setting to avoid anaphylaxia and to develop more clinically relevant protocols to avoid IgE-mediated allergy. This evidence concerns the gene IGHE and allergic disease.